首页 / 产品 / 蛋白 / 信号通路蛋白

Recombinant Human ISR protein

  • 中文名: 胰岛素受体(ISR)重组蛋白
  • 别    名: ISR;Angiotensin-converting enzyme 2
货号: PA1000-8900
Price: ¥询价
数量:
大包装询价

产品详情

纯度>90%SDS-PAGE.
种属Human
靶点ISR
Uniprot NoQ758T2
内毒素< 0.01EU/μg
表达宿主E.coli
表达区间1-342aa
氨基酸序列MSAWASQEAAKEEEAVGDFARMLERRDAGLLARVLSRAQTGPEAYVRGLWRAEVGLERWRLTRVLGCGSVACVFELGDGALALKVPTSRRKAPVLLHEVLIYSHLAQQAGGRLAERHVVPFHGVAAVTRREYRRLRGGEVVPALVLERMDTTLEAVHRRAAVSKGQWWRYARDLVAALQFLRESCVVHGDIKTANVLVRGQDAFLADFTSAAVCDAAPEPLTTTLEYCAPGLIGGGQPTHSTDVYAAGLCLLALITRFEPFRELSMMKSHSSAPTHSLHETQWLMNAISKGDPIKYNVLSQDLYDRWAEELHFLRRFFVPAAQDALSRWLAESNARVAEHAF
预测分子量37,9 kDa
蛋白标签His tag N-Terminus
缓冲液PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
稳定性 & 储存条件Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt.
Reconstituted protein solution can be stored at 2-8°C for 2-7 days.
Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months.
复溶Always centrifuge tubes before opening.Do not mix by vortex or pipetting.
It is not recommended to reconstitute to a concentration less than 100μg/ml.
Dissolve the lyophilized protein in distilled water.
Please aliquot the reconstituted solution to minimize freeze-thaw cycles.

参考文献

以下是3-4条关于ISR(整合应激反应)重组蛋白研究的参考文献概览,按文献名称、作者和摘要内容简要列举:

---

1. **文献名称**:*Recombinant CHOP Protein as a Tool to Study the Integrated Stress Response*

**作者**:H. Harding et al.

**摘要**:研究利用重组CHOP蛋白(ISR下游效应因子)揭示其在内质网应激中的调控机制,证明其通过激活凋亡通路参与细胞应激适应性反应。

2. **文献名称**:*ATF4 Recombinant Protein Modulates Oxidative Stress in Neurodegenerative Models*

**作者**:J. Costa-Mattioli et al.

**摘要**:通过表达重组ATF4蛋白,验证其在神经元中调控抗氧化基因的能力,表明靶向ISR可能为阿尔茨海默病提供治疗策略。

3. **文献名称**:*Production and Functional Analysis of Recombinant ISR Proteins in Bacterial Systems*

**作者**:M. Zhang et al.

**摘要**:优化大肠杆菌表达系统,高效纯化具有生物活性的ISR相关蛋白(如GCN2、PERK),为体外研究应激信号通路提供工具。

4. **文献名称**:*Targeting the ISR with Recombinant Proteins Enhances Cancer Cell Sensitivity to Chemotherapy*

**作者**:S. A. Leung et al.

**摘要**:利用重组ISR调控蛋白(如磷酸化eIF2α突变体)增强肿瘤细胞对化疗的敏感性,揭示通过调节ISR可改善癌症治疗效果。

---

注:以上文献为示例,实际引用需根据具体研究内容核实。建议通过PubMed或Web of Science以关键词“ISR recombinant protein”或“Integrated Stress Response recombinant”检索最新文献。

背景信息

**Background of ISR Recombinant Proteins**

Recombinant proteins engineered for immune system regulation (ISR) represent a pivotal advancement in biotechnology and immunotherapy. These proteins are designed using recombinant DNA technology, which involves inserting genes encoding specific immune-modulating molecules into host organisms (e.g., bacteria, yeast, or mammalian cells) to produce large quantities of purified proteins. The concept emerged alongside breakthroughs in molecular biology during the late 20th century, particularly with the development of gene cloning and expression systems.

ISR recombinant proteins often target key pathways in innate and adaptive immunity. Examples include cytokines (e.g., interleukins, interferons), checkpoint inhibitors (e.g., PD-1/PD-L1 blockers), and antigen-presenting molecules. Their development is driven by the need for precise, scalable, and safer alternatives to traditional therapies, such as chemotherapy or broadly immunosuppressive drugs.

Applications span infectious diseases, cancer immunotherapy, and autoimmune disorders. For instance, recombinant interferon-alpha has been used against viral infections and cancers, while checkpoint inhibitors like recombinant anti-PD-1 antibodies revolutionized oncology by enhancing T-cell-mediated tumor clearance. Challenges include optimizing protein stability, reducing immunogenicity, and ensuring tissue-specific delivery. Recent innovations, such as fusion proteins and glycoengineering, aim to enhance efficacy and half-life.

The field continues to evolve with advances in structural biology, AI-driven protein design, and personalized medicine, positioning ISR recombinant proteins as cornerstone tools in modern therapeutics.

客户数据及评论

折叠内容

大包装询价

×